Price alert —
Sign in to get a one-time email the moment GH crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · GH
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $0.3B | $-0.1B | $-0.1B | $-0.1B | -37.2% | -40.2% |
| 2025-12-31 | $0.3B | $-0.1B | $-0.1B | $-0.1B | -45.7% | -43.0% |
| 2025-09-30 | $0.3B | $-0.1B | $-0.1B | $-0.0B | -35.0% | -37.3% |
| 2025-06-30 | $0.2B | $-0.1B | $-0.1B | $-0.1B | -43.0% | -45.9% |
| 2025-03-31 | $0.2B | $-0.1B | $-0.1B | $-0.1B | -46.8% | -54.6% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare GH vs peers
Line GH up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with GH
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-07 | -0.45 | -0.47 | +5.0% | +3.7% |
| 2026-02-19 | -0.50 | -0.47 | -6.5% | -3.1% |
| 2025-10-29 | -0.39 | -0.49 | +20.3% | +27.9% |
| 2025-07-30 | -0.44 | -0.51 | +14.5% | -9.3% |
| 2025-04-30 | -0.49 | -0.59 | +17.0% | +3.5% |
| 2025-02-20 | -0.62 | -0.50 | -23.1% | -9.6% |
| 2024-11-06 | -0.45 | -0.60 | +24.4% | +13.1% |
| 2024-08-07 | -0.48 | -0.61 | +21.0% | -10.9% |
| 2024-05-09 | -0.46 | -0.73 | +37.0% | +15.1% |
| 2024-02-22 | -0.64 | -0.75 | +14.2% | -12.8% |
| 2023-11-06 | -0.67 | -0.80 | +15.9% | -5.4% |
| 2023-08-03 | -0.82 | -0.93 | +11.5% | +6.4% |
| 2023-05-09 | -1.06 | -1.07 | +1.1% | +14.9% |
| 2023-02-23 | -1.17 | -1.16 | -1.1% | +11.7% |
| 2022-11-03 | -1.18 | -1.08 | -9.4% | +4.9% |
| 2022-08-04 | -1.00 | -0.97 | -3.3% | +3.6% |
| 2022-05-05 | -0.91 | -1.10 | +17.5% | -22.5% |
| 2022-02-23 | -1.15 | -1.08 | -6.1% | +10.0% |
| 2021-11-04 | -1.06 | -0.87 | -21.5% | -4.0% |
| 2021-08-05 | -0.96 | -0.83 | -15.1% | -1.1% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| GH ★ | $20B | — | -347.4 | 18.5 | -49.6 | -109.3 | 64.9% | 48.3% | — | -0.43% |
| LLY | — | 41.2 | 25.8 | — | 29.3 | — | 82.8% | 55.5% | 169.9% | — |
| UNH | $392B | 32.5 | 19.2 | 0.9 | 17.5 | 3.7 | 19.5% | 0.4% | 61.5% | 5.81% |
| JNJ | $602B | 29.0 | 19.5 | 6.1 | 18.1 | 7.4 | 68.1% | 6.6% | -1.0% | — |
| MRK | — | 35.5 | 13.1 | — | 11.9 | 6.8 | 76.7% | 4.9% | — | — |
| ABBV | $451B | 124.6 | 15.7 | 7.2 | 17.1 | -67.8 | 72.0% | 12.4% | -46.2% | 4.61% |
| PFE | — | 19.3 | 8.8 | — | 7.6 | — | 74.8% | 5.4% | -10.1% | — |
| TMO | — | 28.6 | 19.1 | — | 20.9 | — | 40.9% | 6.2% | 11.3% | — |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 41.58%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 11,553,759 | 8.71% |
| Price (T.Rowe) Associates Inc | 7,023,689 | 5.30% |
| Vanguard Portfolio Management LLC | 5,837,992 | 4.40% |
| Vanguard Capital Management LLC | 5,624,180 | 4.24% |
| Invesco Ltd. | 4,946,469 | 3.73% |
| Goldman Sachs Group Inc | 4,435,839 | 3.35% |
| Two Sigma Investments, LP | 4,229,531 | 3.19% |
| FMR, LLC | 4,116,081 | 3.10% |
| BAILLIE GIFFORD & CO | 3,859,046 | 2.91% |
| Geode Capital Management, LLC | 3,508,883 | 2.65% |
Insider activity · 90d
0 buys / 0 sells · ratio 0.0 · Finnhub
- Chudova Darya M 11,903
- Chudova Darya M 16,620
- Chudova Darya M 1,668
- Chudova Darya M 1,340
- Chudova Darya F 78,373 @ $170.77
- Chudova Darya M 82,691
- Chudova Darya M 80,991
- Chudova Darya M 77,667
- Chudova Darya M 76,000
- Kalia Kumud M 9,522
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-07-20 | FORM 4 | view · |
| 4 | 2026-07-16 | FORM 4 | view · |
| 4 | 2026-07-02 | FORM 4 | view · |
| 4 | 2026-07-02 | FORM 4 | view · |
| 4 | 2026-07-02 | FORM 4 | view · |
| 4 | 2026-07-02 | FORM 4 | view · |
| 4 | 2026-07-02 | FORM 4 | view · |
| 4 | 2026-07-02 | FORM 4 | view · |
| 4 | 2026-07-02 | FORM 4 | view · |
| 4 | 2026-07-02 | FORM 4 | view · |
| 4 | 2026-07-02 | FORM 4 | view · |
| 4 | 2026-06-30 | FORM 4 | view · |
| 4 | 2026-06-30 | FORM 4 | view · |
| 4 | 2026-06-23 | FORM 4 | view · |
| 4 | 2026-06-23 | FORM 4 | view · |
| 4 | 2026-06-23 | FORM 4 | view · |
| 4 | 2026-06-22 | FORM 4 | view · |
| 4 | 2026-06-22 | FORM 4 | view · |
| 4 | 2026-06-22 | FORM 4 | view · |
| 4 | 2026-06-22 | FORM 4 | view · |
| 4 | 2026-06-22 | FORM 4 | view · |
| 4 | 2026-06-22 | FORM 4 | view · |
| 4 | 2026-06-22 | FORM 4 | view · |
| 4 | 2026-06-22 | FORM 4 | view · |
| 4 | 2026-06-22 | FORM 4 | view · |
| 8-K | 2026-06-18 | 8-K | view · |
| 4 | 2026-06-17 | FORM 4 | view · |
| 4 | 2026-06-16 | FORM 4 | view · |
| 4 | 2026-06-16 | FORM 4 | view · |
| 4 | 2026-06-16 | FORM 4 | view · |
| 4 | 2026-06-16 | FORM 4 | view · |
| 4 | 2026-06-15 | FORM 4 | view · |
| 4 | 2026-06-12 | FORM 4 | view · |
| 4 | 2026-06-08 | FORM 4 | view · |
| 4 | 2026-06-08 | FORM 4 | view · |
| 4 | 2026-06-05 | FORM 4 | view · |
| 4 | 2026-06-04 | FORM 4 | view · |
| 4 | 2026-06-01 | FORM 4 | view · |
| 4 | 2026-05-29 | FORM 4 | view · |
| 4 | 2026-05-28 | FORM 4 | view · |
| 4 | 2026-05-26 | FORM 4 | view · |
| 4 | 2026-05-22 | FORM 4 | view · |
| 4 | 2026-05-22 | FORM 4 | view · |
| 4 | 2026-05-22 | FORM 4 | view · |
| 4 | 2026-05-22 | FORM 4 | view · |
| 4 | 2026-05-19 | FORM 4 | view · |
| 4 | 2026-05-19 | FORM 4 | view · |
| 4 | 2026-05-19 | FORM 4 | view · |
| 4 | 2026-05-13 | FORM 4 | view · |
| 10-Q | 2026-05-07 | 10-Q | view · |
| 8-K | 2026-05-07 | 8-K | view · |
| 4 | 2026-05-01 | FORM 4 | view · |
| DEF 14A | 2026-04-28 | DEF 14A | view · |
| 8-K | 2026-04-27 | 8-K | view · |
| 4 | 2026-04-22 | FORM 4 | view · |
| 4 | 2026-04-20 | FORM 4 | view · |
| 4 | 2026-04-16 | FORM 4 | view · |
| 4 | 2026-04-16 | FORM 4 | view · |
| 4 | 2026-04-07 | FORM 4 | view · |
| 4 | 2026-04-02 | FORM 4 | view · |
About GH
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based so…
Options picks · GH
ITM + OTM ideas from the latest scanLoading…
Congress trades · GH
STOCK Act disclosuresLoading…
SEC filings & insiders · GH
EDGAR · liveLoading…
Holders · GH
Institutions & insider activityLoading…